Posted by: Dr. Chandrashekhar Potkar
-Clinical Trials Today’s guest author, Dr. Chandrashekhar (Shekhar) Potkar, is the Director of Clinical Research & Regulatory Affairs at Pfizer LTD in Mumbai, India. Over the coming weeks, Dr. Potkar will explore India’s rapid expansion into the clinical trials arena through a series of posts highlighting on one of the hottest topics in the industry today.
Over the last three years, there has been an increase in clinical research activity in India. Rapid expansion of the clinical research activity has lead to number of questions, some with clear answers and others with not so clear answers. This is not necessarily country-specific but perhaps related to the clinical research field itself. As India is poised at a tipping point in this field, we offer a commentary on a range of key topics given below. There have been a number of pointers to this growth, as reflected in...
This commentary aims to provide a balanced perspective on these topics and hopes to clarify some grey areas in this field. Your response, opinions, clarifications, or counterpoints are welcome.
Dr. Potkar, is the Director of Clinical Research & Regulatory Affairs at Pfizer LTD in Mumbai, India and has over 14 years of experience working in the clinical trials industry. He joined Pfizer in 1995 as a Medical Advisor where for over 11 years has collaborated with industry professionals, academia and government in an effort to enhance the clinical research environment in India. He is also a founding governing council and faculty member at the Academy for Clinical Excellence (ACE). Dr. Potkar completed both his postgraduate degree in Pharmacology (M.D.) and MBA from Deakin University. He earned a Master's of Science in Clinical Research at George Washington University.